Logo image of CRBN.AS

CORBION NV (CRBN.AS) Stock Fundamental Analysis

Europe - Euronext Amsterdam - AMS:CRBN - NL0010583399 - Common Stock

18.485 EUR
+0.11 (+0.57%)
Last: 12/30/2025, 5:29:59 PM
Fundamental Rating

5

CRBN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 68 industry peers in the Chemicals industry. CRBN has an average financial health and profitability rating. CRBN is cheap, but on the other hand it scores bad on growth. This makes CRBN very considerable for value investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

CRBN had positive earnings in the past year.
In the past year CRBN had a positive cash flow from operations.
Each year in the past 5 years CRBN has been profitable.
CRBN had a positive operating cash flow in each of the past 5 years.
CRBN.AS Yearly Net Income VS EBIT VS OCF VS FCFCRBN.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

With a decent Return On Assets value of 4.55%, CRBN is doing good in the industry, outperforming 69.12% of the companies in the same industry.
With a decent Return On Equity value of 9.12%, CRBN is doing good in the industry, outperforming 67.65% of the companies in the same industry.
The Return On Invested Capital of CRBN (9.19%) is better than 75.00% of its industry peers.
CRBN had an Average Return On Invested Capital over the past 3 years of 6.62%. This is in line with the industry average of 7.01%.
The 3 year average ROIC (6.62%) for CRBN is below the current ROIC(9.19%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.55%
ROE 9.12%
ROIC 9.19%
ROA(3y)7.34%
ROA(5y)6.93%
ROE(3y)16.91%
ROE(5y)15.8%
ROIC(3y)6.62%
ROIC(5y)7.13%
CRBN.AS Yearly ROA, ROE, ROICCRBN.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

The Profit Margin of CRBN (5.11%) is better than 64.71% of its industry peers.
In the last couple of years the Profit Margin of CRBN has grown nicely.
CRBN's Operating Margin of 8.68% is fine compared to the rest of the industry. CRBN outperforms 63.24% of its industry peers.
In the last couple of years the Operating Margin of CRBN has declined.
With a Gross Margin value of 26.10%, CRBN is not doing good in the industry: 63.24% of the companies in the same industry are doing better.
CRBN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 8.68%
PM (TTM) 5.11%
GM 26.1%
OM growth 3Y1.69%
OM growth 5Y-4.15%
PM growth 3Y26.84%
PM growth 5Y41.37%
GM growth 3Y-0.41%
GM growth 5Y-2.31%
CRBN.AS Yearly Profit, Operating, Gross MarginsCRBN.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CRBN is still creating some value.
CRBN has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRBN has less shares outstanding
Compared to 1 year ago, CRBN has an improved debt to assets ratio.
CRBN.AS Yearly Shares OutstandingCRBN.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CRBN.AS Yearly Total Debt VS Total AssetsCRBN.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 2.74 indicates that CRBN is not a great score, but indicates only limited risk for bankruptcy at the moment.
CRBN has a Altman-Z score of 2.74. This is comparable to the rest of the industry: CRBN outperforms 58.82% of its industry peers.
CRBN has a debt to FCF ratio of 4.95. This is a neutral value as CRBN would need 4.95 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 4.95, CRBN is doing good in the industry, outperforming 72.06% of the companies in the same industry.
CRBN has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.39, CRBN is in line with its industry, outperforming 55.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 4.95
Altman-Z 2.74
ROIC/WACC1.46
WACC6.31%
CRBN.AS Yearly LT Debt VS Equity VS FCFCRBN.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.21 indicates that CRBN should not have too much problems paying its short term obligations.
With a Current ratio value of 1.21, CRBN is not doing good in the industry: 83.82% of the companies in the same industry are doing better.
A Quick Ratio of 0.60 indicates that CRBN may have some problems paying its short term obligations.
CRBN has a worse Quick ratio (0.60) than 91.18% of its industry peers.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 0.6
CRBN.AS Yearly Current Assets VS Current LiabilitesCRBN.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

3

3. Growth

3.1 Past

The earnings per share for CRBN have decreased strongly by -68.99% in the last year.
CRBN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 49.47% yearly.
The Revenue has been growing slightly by 2.95% in the past year.
CRBN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.70% yearly.
EPS 1Y (TTM)-68.99%
EPS 3Y34.95%
EPS 5Y49.47%
EPS Q2Q%-74.51%
Revenue 1Y (TTM)2.95%
Revenue growth 3Y6.35%
Revenue growth 5Y5.7%
Sales Q2Q%1.33%

3.2 Future

The Earnings Per Share is expected to grow by 15.24% on average over the next years. This is quite good.
CRBN is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.71% yearly.
EPS Next Y36.6%
EPS Next 2Y22.97%
EPS Next 3Y19.62%
EPS Next 5Y15.24%
Revenue Next Year-2.4%
Revenue Next 2Y-0.19%
Revenue Next 3Y1.19%
Revenue Next 5Y-1.71%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRBN.AS Yearly Revenue VS EstimatesCRBN.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B
CRBN.AS Yearly EPS VS EstimatesCRBN.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 16.50, which indicates a correct valuation of CRBN.
73.53% of the companies in the same industry are more expensive than CRBN, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.77, CRBN is valued a bit cheaper.
A Price/Forward Earnings ratio of 12.15 indicates a correct valuation of CRBN.
79.41% of the companies in the same industry are more expensive than CRBN, based on the Price/Forward Earnings ratio.
CRBN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.35, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 16.5
Fwd PE 12.15
CRBN.AS Price Earnings VS Forward Price EarningsCRBN.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CRBN is valued a bit cheaper than 66.18% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRBN indicates a rather cheap valuation: CRBN is cheaper than 91.18% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 10.79
EV/EBITDA 7.73
CRBN.AS Per share dataCRBN.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

CRBN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of CRBN may justify a higher PE ratio.
CRBN's earnings are expected to grow with 19.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.45
PEG (5Y)0.33
EPS Next 2Y22.97%
EPS Next 3Y19.62%

6

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 3.52%, CRBN has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 2.51, CRBN pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.00, CRBN pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.52%

5.2 History

The dividend of CRBN has a limited annual growth rate of 5.02%.
Dividend Growth(5Y)5.02%
Div Incr Years1
Div Non Decr Years5
CRBN.AS Yearly Dividends per shareCRBN.AS Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

CRBN pays out 56.19% of its income as dividend. This is a bit on the high side, but may be sustainable.
CRBN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP56.19%
EPS Next 2Y22.97%
EPS Next 3Y19.62%
CRBN.AS Yearly Income VS Free CF VS DividendCRBN.AS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M
CRBN.AS Dividend Payout.CRBN.AS Dividend Payout, showing the Payout Ratio.CRBN.AS Dividend Payout.PayoutRetained Earnings

CORBION NV

AMS:CRBN (12/30/2025, 5:29:59 PM)

18.485

+0.11 (+0.57%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)07-31 2025-07-31
Earnings (Next)N/A N/A
Inst Owners90.59%
Inst Owner ChangeN/A
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap1.08B
Revenue(TTM)1.30B
Net Income(TTM)66.20M
Analysts78.57
Price Target23.92 (29.4%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.52%
Yearly Dividend0.71
Dividend Growth(5Y)5.02%
DP56.19%
Div Incr Years1
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.51%
PT rev (3m)2.29%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.61%
Revenue NY rev (3m)-1.59%
Valuation
Industry RankSector Rank
PE 16.5
Fwd PE 12.15
P/S 0.83
P/FCF 10.79
P/OCF 6.39
P/B 1.48
P/tB 1.7
EV/EBITDA 7.73
EPS(TTM)1.12
EY6.06%
EPS(NY)1.52
Fwd EY8.23%
FCF(TTM)1.71
FCFY9.27%
OCF(TTM)2.89
OCFY15.65%
SpS22.26
BVpS12.47
TBVpS10.88
PEG (NY)0.45
PEG (5Y)0.33
Graham Number17.72
Profitability
Industry RankSector Rank
ROA 4.55%
ROE 9.12%
ROCE 10.92%
ROIC 9.19%
ROICexc 9.57%
ROICexgc 10.55%
OM 8.68%
PM (TTM) 5.11%
GM 26.1%
FCFM 7.7%
ROA(3y)7.34%
ROA(5y)6.93%
ROE(3y)16.91%
ROE(5y)15.8%
ROIC(3y)6.62%
ROIC(5y)7.13%
ROICexc(3y)7.16%
ROICexc(5y)7.83%
ROICexgc(3y)8.31%
ROICexgc(5y)9.44%
ROCE(3y)7.87%
ROCE(5y)8.47%
ROICexgc growth 3Y0.82%
ROICexgc growth 5Y-11.84%
ROICexc growth 3Y3.78%
ROICexc growth 5Y-8.06%
OM growth 3Y1.69%
OM growth 5Y-4.15%
PM growth 3Y26.84%
PM growth 5Y41.37%
GM growth 3Y-0.41%
GM growth 5Y-2.31%
F-Score6
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 4.95
Debt/EBITDA 1.43
Cap/Depr 81.01%
Cap/Sales 5.3%
Interest Coverage 7.03
Cash Conversion 85.4%
Profit Quality 150.76%
Current Ratio 1.21
Quick Ratio 0.6
Altman-Z 2.74
F-Score6
WACC6.31%
ROIC/WACC1.46
Cap/Depr(3y)194.04%
Cap/Depr(5y)192.31%
Cap/Sales(3y)11.51%
Cap/Sales(5y)11.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-68.99%
EPS 3Y34.95%
EPS 5Y49.47%
EPS Q2Q%-74.51%
EPS Next Y36.6%
EPS Next 2Y22.97%
EPS Next 3Y19.62%
EPS Next 5Y15.24%
Revenue 1Y (TTM)2.95%
Revenue growth 3Y6.35%
Revenue growth 5Y5.7%
Sales Q2Q%1.33%
Revenue Next Year-2.4%
Revenue Next 2Y-0.19%
Revenue Next 3Y1.19%
Revenue Next 5Y-1.71%
EBIT growth 1Y54.53%
EBIT growth 3Y8.15%
EBIT growth 5Y1.31%
EBIT Next Year128.83%
EBIT Next 3Y37.35%
EBIT Next 5Y26.73%
FCF growth 1Y171.85%
FCF growth 3YN/A
FCF growth 5Y21.2%
OCF growth 1Y118.83%
OCF growth 3Y101.81%
OCF growth 5Y9.98%

CORBION NV / CRBN.AS FAQ

What is the fundamental rating for CRBN stock?

ChartMill assigns a fundamental rating of 5 / 10 to CRBN.AS.


Can you provide the valuation status for CORBION NV?

ChartMill assigns a valuation rating of 7 / 10 to CORBION NV (CRBN.AS). This can be considered as Undervalued.


What is the profitability of CRBN stock?

CORBION NV (CRBN.AS) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for CRBN stock?

The Price/Earnings (PE) ratio for CORBION NV (CRBN.AS) is 16.5 and the Price/Book (PB) ratio is 1.48.


Can you provide the dividend sustainability for CRBN stock?

The dividend rating of CORBION NV (CRBN.AS) is 6 / 10 and the dividend payout ratio is 56.19%.